VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
Click Here to Manage Email Alerts
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
Data on several approved and investigational drugs were presented at the conference, including osilodrostat (Isturisa, Recordati) for the treatment of Cushing’s disease and oral octreotide (Mycapssa, Chiasma), once-monthly octreotide (Camurus) and oral paltusotine (Crinetics Pharmaceuticals) for the treatment of acromegaly. Fleseriu, who is professor of medicine and neurological surgery and director of the Oregon Health & Science University Pituitary Center and a Healio | Endocrine Today Co-editor, talks about some of the key findings and how they may impact people with those conditions.
Fleseriu also previews an upcoming scientific statement from The Endocrine Society on the effects of exogenous opioids on the endocrine system.
“[The statement] includes effects on pituitary and adrenal function,” Fleseriu said. “This is a topic that sometimes is missed in our practice.”
Collapse
Click Here to Manage Email Alerts